Diego is a co-founder, board member, and Chief Scientific Officer of Endpoint Health, a precision immunology therapeutics company. Prior to co-founding Endpoint Health, Diego invented the core ...
High-level results from the CALYPSO Phase III trial showed that eneboparatide, AZP-3601, an investigational parathyroid hormone receptor 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback